Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles.
Mantle cell lymphoma (MCL) is an entity which exceptionally affects the ocular region and periorbital tissues, but which should be included in the differential diagnosis of lesions which affect the orbital region in a diffused manner. We report the case of a 60-year-old patient diagnosed with stage IV MCL, whose fi rst clinical manifestation was a result of the damage of lacrimal glands, retro-orbital tissue and ocular motor muscles. The patient was treated with rituximab and chemotherapy, achieving a complete response of those lesions.
Pajares-Hachero
Bella
B
Medical Oncology Department, Hospital Clínico Virgen de la Victoria, Campus Universitario Teatinos, Málaga, Spain. bellapajares@yahoo.es
Torres
Esperanza
E
Hierro
Isabel
I
Jurado
José Miguel
JM
Rueda
Antonio
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005123:Eye / Q000473:pathology; D005142:Eyelid Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007765:Lacrimal Apparatus / Q000473:pathology*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009900:Optic Nerve / Q000473:pathology*; D009918:Orbital Neoplasms / Q000188:drug therapy / Q000473:pathology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab